Risk Of Developing Liver Cancer After HCV Treatment

▼
Showing posts with label Miravirsen. Show all posts
Showing posts with label Miravirsen. Show all posts
Tuesday, August 27, 2013

Hepatitis C-Miravirsen: Santaris Pharma A/S Completes Enrollment in Phase 2 Clinical Trial

›
Also See Updates On The Website Sept 2013 - Miravirsen: Antisense therapy for hepatitis C COMMENTARY ON: Treatment of HCV infection by ta...
Thursday, June 6, 2013

Miravirsen-Treating hepatitis C by blocking a cellular microRNA

›
Podcast: Download TWiV 235 Treating hepatitis C by blocking a cellular microRNA Miravirsen is a drug that binds to and blocks the funct...
Wednesday, May 15, 2013

Hepatitis C Therapy Update 2013-What About Interferon-free Regimens?

›
Current Opinion in Gastroenterology Hepatitis C Virus Therapy Update 2013 Lisa C. Casey, William M. Lee Curr Opin Gastroenterol. 2013;29(3...
Thursday, March 28, 2013

Watch - Miravirsen: First microRNA-targeted drug effective for hepatitis C

›
Uploaded Mar 27 - UMassMedicalSchool · Miravirsen, the first microRNA-targeted drug to enter human clinical trials, successfully reduc...
Wednesday, March 27, 2013

Miravirsen- Hepatitis C drug goes after patients’ RNA

›
Hepatitis C drug goes after patients’ RNA      Compound targets genetic material that virus uses for replicating By Nathan Seppa ...
Thursday, April 19, 2012

EASL-Final Phase 2a Study Results For Miravirsen Showing Dose-dependent, Prolonged Antiviral Activity In Hepatitis C Patients

›
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will pre...
Sunday, November 13, 2011

AASLD: MicroRNA Drug Safe in Ongoing HCV Study

›
By Michael Smith, North American Correspondent, MedPage Today Published: November 12, 2011 Reviewed by Robert Jasmer, MD ; Associate Clini...
Saturday, November 5, 2011

AASLD-Santaris Phase 2a Data of Miravirsen Shows Dose-Dependent, Prolonged Viral Reduction of 2-3 Logs HCV RNA After Four-Week

›
Santaris Pharma A/S Phase 2a Data of Miravirsen Shows Dose-Dependent, Prolonged Viral Reduction of 2-3 Logs HCV RNA After Four-Week Treatmen...